TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06084897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
Description: A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
Description: A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation Radiation
Description: IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66Gy/19f or 40Gy/20f for organ metastasis patients. Radiation treatment is planned after chemotherapy completed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage Radiation
Description: IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66\~49.22Gy/19f \~23f or 40\~50Gy/20\~25f for organ metastasis patients. Radiation treatment is planned after disease progression when recommended by multidisciplinary team.
Study: NCT05004584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat home-based appetite assessment
Description: Home-based appetite assessment with diet based on wheat cereal products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye home-based appetite assessment
Description: Home-based appetite assessment with diet based on rye cereal products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat clinic-based appetite assessment
Description: Clinic-based appetite assessment with diet based on wheat cereal products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye clinic-based appetite assessment
Description: Clinic-based appetite assessment with diet based on rye cereal products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye/Wheat clinic-based appetite assessment with blood sampling
Description: Clinic-based appetite assessment with diet based on rye or wheat cereal products and continuous blood sampling.
Study: NCT06104995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional video
Description: The educational video comprises of health care professionals explaining the durability of the back against the popular belief that the back is fragile and the multifactorial nature of back pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control video
Description: The control video is a neutral video with no content addressing back beliefs (fragility and need for protection).
Study: NCT06506851

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional Guideline-based Self-Learning
Description: Practical nurses in this group follow traditional guideline-based self-learning methods without augmented reality technology. They rely on conventional educational materials and guidelines for learning device utilization skills.
Study: NCT06248190

Intervention type: OTHER
Group type: OTHER
Intervention: ENHANCE intervention (health systems)
Description: The intervention tools include a consolidated clinical decision support tool, health education posters, waiting room talks, medication list for treatment literacy and a patient health diary. Training session are delivered at all intervention sites and include 1 facility team session to introduce the ENHANCE study to the whole team; 3 clinical sessions for nurses and doctors; 2 sessions for community health workers and health promoters; Maintenance sessions to keep the ENHANCE intervention going for at least 12 months
Study: NCT05620407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05660018

Intervention type: DEVICE
Group type: OTHER
Intervention: active rTMS first, then sham rTMS
Description: Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.

Intervention type: DEVICE
Group type: OTHER
Intervention: sham rTMS first, then active rTMS
Description: Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.
Study: NCT04899661

Intervention type: DRUG
Intervention: Molidustat (Musredo, BAY85-3934)
Description: Tablets, administered orally at the discretion of investigators
Study: NCT05504239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
Description: To be orally administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teneligliptin Placebo Oral Tablet
Description: To be orally administered once daily
Study: NCT05492578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Description: Pharmaceutical form: Topical Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form: Topical Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Description: Pharmaceutical form: Oral Route of administration: Oral
Study: NCT06029517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Receive Indigneous SIPin intervention
Study: NCT05588908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
Description: 100 mg subcutaneous (s.c) once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)
Description: 200 mg subcutaneous (s.c) once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)
Description: 300 mg subcutaneous (s.c) once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)
Description: one s.c. injection of SSGJ-613 once, on Day 1.
Study: NCT05838794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mckenzie exercise for neck
Description: The McKenzie protocol will be used to manage extension, rotation, and lateral flexion dysfunctions in patients with non-specific neck pain. An experienced physical therapist will perform the protocol 3 times a week for 6 weeks, tailoring exercises to each patient's individual needs based on limited and painful directions of movement. Exercises include retraction, extension, rotation, lateral flexion, and overpressure techniques. Patients will receive education on posture and body mechanics, and exercises will be progressed over time as the patient improves.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mckenzie exercise for neck
Description: The McKenzie protocol will be used to manage extension, rotation, and lateral flexion dysfunctions in patients with non-specific neck pain. An experienced physical therapist will perform the protocol 3 times a week for 6 weeks, tailoring exercises to each patient's individual needs based on limited and painful directions of movement. Exercises include retraction, extension, rotation, lateral flexion, and overpressure techniques. Patients will receive education on posture and body mechanics, and exercises will be progressed over time as the patient improves.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercise
Description: Cervical and scapulothoracic stabilization exercises will be performed by an experienced physical therapist 3 times a week for 6 weeks, with each session including a warm-up, stabilization exercises, and cool-down and stretching exercises. Postural education will be provided using mirrors to find a neutral balanced position, and the cervical bracing technique with deep neck flexor activation will be used to stabilize the cervical spine. Upper extremity range of motion exercises and cervical dynamic isometric exercises with elastic resistive bands will also be performed. Scapulothoracic stabilization exercises will include specific exercises for muscles affecting scapular orientation related to neck pain, using latex bands with mild or medium tension.
Study: NCT04746781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile 360° Video intervention
Description: Using 360° Videos to educate participants about the effect of diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation and Problem Solving (MAPS)
Description: Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk notification/education
Description: Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk notification/education
Description: Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk notification/education
Description: Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
Study: NCT04701749

Intervention type: DEVICE
Intervention: Percutaneous left atrial closure
Description: Percutaneous left atrial closure was performed under general anesthesia with angiographic control and transesophageal echocardiography. The procedure takes between 15 and 20 minutes. This begins with a right femoral venipuncture, progression of the guide in the right atrium allowing atrial trans-septal puncture to catheterize the left atrium. A nitinol prosthesis is implanted (Boston Watchman) at the ostium of the left auricle between the left superior pulmonary vein and the circumflex artery. After a tensile test verifying the stability of the prosthesis, the absence of peri-prosthetic leakage is verified by ETO and angiographic control. The patient is monitored 48 hours before discharge to eliminate the appearance of pericardial effusion and prosthetic embolization. Aspirin 75 mg monotherapy is started the same day with stopping anticoagulation.

Intervention type: OTHER
Intervention: No Percutaneous left atrial closure
Description: No Percutaneous left atrial closure
Study: NCT04885465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based psychoeducational support
Description: Caregivers in the experimental group will have access to psycho-educational support through a web-based plattform during 3 months.
Study: NCT05588908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)
Description: one s.c. injection of SSGJ-613 once, on Day 1.
Study: NCT04400227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Talk
Description: Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness.
Study: NCT05588908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Betamethasone Injection (phase II)
Description: 1 mL i.m. once on Day 1
Study: NCT06029517

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: Complete interviews

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Discussion
Description: Attend focus groups
Study: NCT05614752

Intervention type: DRUG
Intervention: Fexuprazan
Description: Fexuclue Tablet 40mg
Study: NCT06295796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Oral Capsule
Study: NCT06514898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-DC vaccines with GM-CSF
Description: After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.~up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment)
Study: NCT06206707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Faecal Microbiota Transplantation (FMT)
Description: Capsule FMT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04951180

Intervention type: OTHER
Intervention: Demographic data and MRI images extraction
Description: The data were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.
Study: NCT06514898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-xALT
Description: All participants will receive a single infusion of T-cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Td vaccine
Description: A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #5, #7 and #9.
Study: NCT05264740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: The control group will receive educational material only.
Study: NCT06175754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser ablation
Description: Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser with Sclerotherapy
Description: Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy
Study: NCT06514898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous HSCs
Description: All participants will receive a single intravenous infusion of autologous HSCs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive PD-1 blockade IV starting with ACT continuing for up to 2 years as long as tolerable and without disease progression.
Study: NCT06286033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-181
Description: AG-181 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-181
Description: AG-181 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-181
Description: AG-181 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-181
Description: AG-181 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AG-181 matched-placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AG-181 matched-placebo tablets
Study: NCT04882878

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
Study: NCT05063539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: given orally
Study: NCT05181618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
Study: NCT05668325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini trampoline exercise group
Description: In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: In this study, patients were visited at home once a week for eight weeks and their feet were checked.
Study: NCT04961567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.
Study: NCT06369233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MegaShield®-SP
Description: MegaShield®-SP application Lumbar discectomy or laminectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guardix-SP Plus
Description: Guardix-SP Plus application Lumbar discectomy or laminectomy
Study: NCT05296538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broad-Minded Affective Coping Intervention
Description: The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Assessment and Signposting
Description: A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.

Intervention type: OTHER
Group type: OTHER
Intervention: Risk Assessment and Signposting
Description: A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
Study: NCT04517110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Description: Pregabalin 300 mg, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Description: Pregabalin 75 mg twice daily, capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin 300 mg Placebo
Description: Placebo, matching Pregabalin 300 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin 75 mg Placebo
Description: Placebo, matching Pregabalin 75 mg capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care
Study: NCT04646226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV graft
Description: The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical intervention for creation of a fistula
Description: The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)